These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

963 related articles for article (PubMed ID: 28778958)

  • 21. Combining
    Woff E; Kehagias P; Vandeputte C; Ameye L; Guiot T; Paesmans M; Hendlisz A; Flamen P
    J Nucl Med; 2019 Oct; 60(10):1366-1372. PubMed ID: 30850494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
    Lyskjær I; Kronborg CS; Rasmussen MH; Sørensen BS; Demuth C; Rosenkilde M; Johansen AFB; Knudsen M; Vang S; Krag SRP; Spindler KG; Andersen CL
    Sci Rep; 2019 Aug; 9(1):11542. PubMed ID: 31395942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
    Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
    J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.
    Zhuang R; Li S; Li Q; Guo X; Shen F; Sun H; Liu T
    PLoS One; 2017; 12(8):e0182562. PubMed ID: 28796802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
    Xie W; Xie L; Song X
    Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
    Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A systematic review and meta-analysis.
    Ye P; Cai P; Xie J; Wei Y
    PLoS One; 2021; 16(3):e0248775. PubMed ID: 33770081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
    Ai B; Liu H; Huang Y; Peng P
    Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.
    Elez E; Chianese C; Sanz-García E; Martinelli E; Noguerido A; Mancuso FM; Caratù G; Matito J; Grasselli J; Cardone C; Esposito Abate R; Martini G; Santos C; Macarulla T; Argilés G; Capdevila J; Garcia A; Mulet N; Maiello E; Normanno N; Jones F; Tabernero J; Ciardello F; Salazar R; Vivancos A
    Mol Oncol; 2019 Sep; 13(9):1827-1835. PubMed ID: 31322322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis.
    Cargnin S; Canonico PL; Genazzani AA; Terrazzino S
    J Thorac Oncol; 2017 Jan; 12(1):43-53. PubMed ID: 27543256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma.
    Delfau-Larue MH; van der Gucht A; Dupuis J; Jais JP; Nel I; Beldi-Ferchiou A; Hamdane S; Benmaad I; Laboure G; Verret B; Haioun C; Copie-Bergman C; Berriolo-Riedinger A; Robert P; Casasnovas RO; Itti E
    Blood Adv; 2018 Apr; 2(7):807-816. PubMed ID: 29636326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
    Vymetalkova V; Cervena K; Bartu L; Vodicka P
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
    Thierry AR
    Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.
    El Messaoudi S; Mouliere F; Du Manoir S; Bascoul-Mollevi C; Gillet B; Nouaille M; Fiess C; Crapez E; Bibeau F; Theillet C; Mazard T; Pezet D; Mathonnet M; Ychou M; Thierry AR
    Clin Cancer Res; 2016 Jun; 22(12):3067-77. PubMed ID: 26847055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
    Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
    Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
    Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
    Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis - an update.
    Molnár B; Galamb O; Kalmár A; Barták BK; Nagy ZB; Tóth K; Tulassay Z; Igaz P; Dank M
    Expert Rev Mol Diagn; 2019 Jun; 19(6):477-498. PubMed ID: 31046485
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.